Oral Mucosal Changes: Early Detection of Potentially Malignant Oral Lesions (OPMD) — Diagnostics, Biomarkers, and Therapeutic Options
The early detection of oral cancer precursors remains one of the biggest unresolved challenges in dental practice—balancing clear prognostic advantage against a lack of validated screening tools.
Orientation Before Reading
Critical Axes and Publication Boundaries
- Article Type: Diagnostics. The topic is organized across five clinical decision axes, not through a single global judgment.
- Evidence Basis: High / Strong / Fully Rated. 11 systematic reviews and meta-analyses, 5 green / 6 yellow / 0 red.
- Bias Risk: Low to moderate. CoI Risk: low. Source Integrity: clean.
- Decision Axes: (1) Early Detection and Prognosis, (2) Biopsy as Gold Standard, (3) AI-assisted Diagnostics, (4) Salivary Biomarkers, (5) Curcumin for OPMD.
Clinical Question
What diagnostic and therapeutic options are available for potentially malignant oral lesions (OPMD)—and how should their evidence base be classified? At what point should a mucosal lesion prompt consideration of malignancy, monitoring, biopsy, or referral?
Executive Summary
The local body of literature includes 11 systematic reviews and meta-analyses on the topic of OPMD. The overall evidence base is supportive: 5 sources are classified as supporting (green), and 6 with reservations (yellow). No source falls into the critical category.